Peijia Medical Limited (HKG:9996)

Market Cap	3.06B
Revenue (ttm)	556.01M
Net Income (ttm)	-270.49M
Shares Out	654.14M
EPS (ttm)	-0.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,784,000
Average Volume	2,159,309
Open	4.960
Previous Close	4.750
Day's Range	4.590 - 4.960
52-Week Range	2.160 - 5.380
Beta	0.47
RSI	61.92
Earnings Date	Mar 28, 2025

About Peijia Medical

Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusMax, an iteration steerable TAVR system; TaurusTrio, a TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymeric leaflet TAVR system; Tri...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2012
• Employees: 973
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9996

Financial Performance

In 2023, Peijia Medical's revenue was 441.13 million, an increase of 75.86% compared to the previous year's 250.83 million. Losses were -392.53 million, -3.75% less than in 2022.

Financial numbers in CNY